Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report issued on Monday, Benzinga reports. They presently have a $140.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target suggests a potential upside of 15.05% from the company’s previous close. […]
Sarepta Therapeutics (NASDAQ:SRPT) Given Buy Rating at Needham & Company LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Sarepta Therapeutics, Inc (NASDAQ:SRPT) Short Interest Update wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
NBC Securities Inc. purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 6,160 shares of the biotechnology company’s stock, valued at approximately $746,000. Several other institutional investors also […]
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $151 00 at Royal Bank of Canada theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.